Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of SUVN-G3031 in Healthy Subjects (Food, Gender, Age)
NCT02881294Phase 1Completed
- Sponsor
- Suven Life Sciences
- Start
- Aug 2016
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Samelisant in cognitive disorder (CD) (3 arms), sponsored by Suven Life Sciences. Primary endpoints: Area under concentration at 96 hours and Maximum observed concentration at Day 1. Started Aug 2016; status: completed.
02
Drugs
Samelisant
03
Conditions
cognitive disorder (CD)
Beyond the preview
Go deeper on NCT02881294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02881294.